GC
GH icon

Guggenheim Capital’s Guardant Health GH Stock Holding History

Guggenheim Capital’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Sell
73,753
-4,261
-5% -$463K 0.07% 269
2026
Q1 		$7.21M Buy
78,014
+16,044
+26% +$1.61M 0.06% 350
2025
Q4 		$6.33M Sell
61,970
-2,244
-3% -$201K 0.05% 374
2025
Q3 		$4.01M Sell
64,214
-23,056
-26% -$1.25M 0.03% 502
2025
Q2 		$4.54M Buy
87,270
+2,111
+2% +$94.3K 0.04% 447
2025
Q1 		$3.63M Sell
85,159
-28,691
-25% -$1.24M 0.03% 497
2024
Q4 		$3.48M Sell
113,850
-11,830
-9% -$333K 0.03% 516
2024
Q3 		$2.88M Sell
125,680
-12,131
-9% -$343K 0.02% 697
2024
Q2 		$3.98M Sell
137,811
-17,372
-11% -$405K 0.03% 589
2024
Q1 		$3.2M Sell
155,183
-6,626
-4% -$142K 0.02% 725
2023
Q4 		$4.38M Buy
161,809
+11,480
+8% +$301K 0.03% 564
2023
Q3 		$4.46M Buy
150,329
+17,321
+13% +$609K 0.04% 526
2023
Q2 		$4.76M Buy
133,008
+8,946
+7% +$257K 0.04% 537
2023
Q1 		$2.91M Buy
124,062
+7,284
+6% +$208K 0.02% 720
2022
Q4 		$3.18M Buy
116,778
+644
+0.6% +$29.5K 0.03% 691
2022
Q3 		$6.25M Buy
116,134
+7,090
+7% +$364K 0.06% 419
2022
Q2 		$4.4M Buy
109,044
+8,033
+8% +$398K 0.03% 601
2022
Q1 		$6.69M Buy
101,011
+29,270
+41% +$2M 0.04% 538
2021
Q4 		$7.17M Buy
71,741
+20,194
+39% +$2.09M 0.04% 537
2021
Q3 		$6.44M Buy
51,547
+6,504
+14% +$773K 0.04% 553
2021
Q2 		$5.59M Buy
45,043
+4,147
+10% +$558K 0.03% 640
2021
Q1 		$6.24M Buy
40,896
+4,978
+14% +$752K 0.04% 534
2020
Q4 		$4.63M Sell
35,918
-4,662
-11% -$536K 0.03% 607
2020
Q3 		$4.54M Sell
40,580
-16,026
-28% -$1.47M 0.03% 566
2020
Q2 		$4.59M Buy
56,606
+10,397
+22% +$838K 0.04% 549
2020
Q1 		$3.22M Sell
46,209
-10,153
-18% -$779K 0.03% 617
2019
Q4 		$4.4M Buy
+56,362
New +$4.06M 0.03% 687

Other funds holding GH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Guggenheim Capital's GH Position: Q2 2026 in Review

Guggenheim Capital reduced its Guardant Health (GH) stake by 5.5% in Q2 2026, selling an estimated $463K and leaving 73,753 shares worth $11.1M. The position accounts for 0.07% of the portfolio, ranked #269.

Guggenheim Capital first reported a position in GH in Q4 2019 and has held it in 27 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • Guggenheim Capital held 73,753 shares of Guardant Health worth $11.1M as of Q2 2026.
  • Guggenheim Capital sold 4,261 Guardant Health shares in Q2 2026, an estimated $463K.
  • Guardant Health made up 0.07% of Guggenheim Capital's portfolio in Q2 2026, its #269 holding.
  • Guggenheim Capital first reported a position in Guardant Health in Q4 2019 and has held it in 27 quarters since.
  • 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.